Research programme: nuclear receptor inhibitors - Almirall/Nuevolution
Alternative Names: RORγt inhibitor - Almirall/Nuevolution; RORγt inhibitor - Nuevolution/Almirall; RORγt inverse agonist - Almirall/Nuevolution; RORγt inverse agonist - Nuevolution/AlmirallLatest Information Update: 28 Oct 2021
At a glance
- Originator Nuevolution
- Developer Almirall S.A.; Nuevolution
- Class Anti-inflammatories; Small molecules
- Mechanism of Action Nuclear receptor subfamily 1 group F member 3 inverse agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammatory bowel diseases; Psoriatic arthritis; Rheumatoid arthritis
Most Recent Events
- 28 Oct 2021 No recent reports of development identified for preclinical development in Inflammatory-bowel-diseases in Denmark (PO, Tablet)
- 28 Oct 2021 No recent reports of development identified for preclinical development in Inflammatory-bowel-diseases in Spain (PO, Tablet)
- 28 Jan 2021 No recent reports of development identified for preclinical development in Psoriatic-arthritis in Denmark (PO, Tablet)